Results 61 to 70 of about 10,317 (226)
Sweet taste loss in myasthenia gravis: more than a coincidence? [PDF]
Sweet dysgeusia, a rare taste disorder, may be encountered in severe anti-acetylcholine receptor antibody (AChRAb)-myasthenia gravis (MG). A 42 year-old man reported progressive loss of sweet taste evolving for almost 10 weeks, revealing an AChRAb ...
Chabwine, J.N. +4 more
core +5 more sources
Abstract Immune checkpoint inhibitor (ICI) therapies have revolutionised the management of a range of malignancies. However, the syndrome of ICI induced cardiomyotoxicity, also reported as triple “M” syndrome (myasthenia gravis, myositis and myocarditis) is an unfortunate severe consequence in up to 1%–2% of patients receiving ICI, with an associated ...
S. Z. Xie +14 more
wiley +1 more source
Isotonic tongue endurance was measured pre‐ and post‐meal using the Iowa Oral Performance Instrument (IOPI) in healthy younger (18–35 years) and older (≥ 65 years) adults. Older adults demonstrated greater isotonic endurance and longer mealtimes, with no sex differences in endurance.
Yvette M. McCoy +8 more
wiley +1 more source
Disfagia e Disartria. Forma Invulgar de Apresentação da Miastenia Gravis [PDF]
Myasthenia Gravis is an autoimmune disorder that generally presents with ocular symptoms, specially diplopia and ptosis. Dysphagia may be a manifestation of the generalised type of the disease, but rarely is its presenting feature. The authors describe a
Alcântara, J +5 more
core
Abstract This study examines whether underwriting methods—representation, medical examination, extra premiums, and coverage—effectively mitigate adverse selection using data from an insurance company. Regarding representation, we focus on statements disclosing pre‐existing medical conditions.
Chia‐Ling Ho +3 more
wiley +1 more source
The evaluation of approaches to the treatment of myasthenia gravis.
Myasthenia gravis is a relatively rare autoimmune disease with an undetermined aetiology which affects neuromuscular junctions. Currently, the following approaches to the treatment of myasthenia gravis are mainly distinguished: symptomatic treatment with
O. I. Kalbus +4 more
doaj +1 more source
Neurological complications of immune checkpoint inhibitors: what happens when you \u27take the brakes off\u27 the immune system. [PDF]
Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications.
Dalakas, Marinos
core +1 more source
Retrospective Evaluation of Dual Specialty Ports in Therapeutic Apheresis
ABSTRACT Dual specialty ports were evaluated for safety and efficacy in therapeutic apheresis by analyzing outcomes across 97 port placement events in 88 patients, focusing on two configurations: dual Bard PowerFlow (BP2) and a combination of Bard PowerFlow with AngioDynamics SmartPort (BP + AD).
Mugtaba Swar‐Eldahab +3 more
wiley +1 more source
An update on myasthenia gravis [PDF]
Myasthenia gravis (MG) is an autoimmune disease characterised by autoantibodies against acetylcholine receptors at neuromuscular junctions, resulting in defective neuromuscular transmission.
Chan, KH, Ho, SL
core
Class A drug abuse: an ophthalmologist's problem? [PDF]
[First Paragraph] The 2002/3 British Crime Survey reported that 3% of all 16 to 59 year olds (equating to around one million people) had used a class A drug in the last year.
Firth, A.Y.
core +1 more source

